FDA: Sirturo (bedaquiline) approved as part of combination therapy to treat adults with pulmonary MDR-TB

On Dec. 28, the U.S. Food and Drug Administration approved Sirturo (bedaquiline) as part of combination therapy to treat adults with multi-drug resistant pulmonary tuberculosis (TB) when other alternatives are not available.